Related Experiment Videos
Labetalol does not lengthen asystole during electroconvulsive therapy
P N Dannon1, I Iancu, S Hirschmann
1Chaim Sheba Medical Center, Psychiatry Division, Tel Hashomer, Israel.
The Journal of ECT
|January 1, 1999
Summary
Labetalol administration during electroconvulsive therapy (ECT) did not cause severe bradycardia in 32 patients, even without anticholinergic drugs. This suggests premedication is not routinely necessary to prevent adverse cardiac effects during ECT.
Area of Science:
- Anesthesiology
- Cardiology
- Pharmacology
Background:
- Labetalol, an alpha- and beta-blocker, is used to manage hemodynamic changes during electroconvulsive therapy (ECT).
- Concerns exist regarding potential severe bradycardia when labetalol is used during ECT without anticholinergic premedication.
Purpose of the Study:
- To evaluate the safety and efficacy of labetalol administration during ECT without anticholinergic premedication.
- To assess the incidence of bradycardic effects in patients receiving labetalol during ECT.
Main Methods:
- Retrospective review of 32 patients of all age groups who received labetalol during ECT.
- Patients did not receive anticholinergic premedication prior to ECT and labetalol administration.
Main Results:
- No patients experienced adverse bradycardic effects.
- Labetalol administration did not appear to lengthen asystole during ECT.
- The study found no significant adverse cardiac events related to labetalol use.
Conclusions:
- Routine anticholinergic premedication is not necessary when administering labetalol during ECT.
- Labetalol can be safely used during ECT without anticholinergic agents.
- The findings support the use of labetalol for hemodynamic management during ECT without increased risk of bradycardia.